Lee Nancy, Nehmeh Sadek, Schöder Heiko, Fury Matthew, Chan Kelvin, Ling C Clifton, Humm John
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):101-8. doi: 10.1016/j.ijrobp.2008.10.049. Epub 2009 Feb 7.
To report the results from a prospective study of a series of locoregionally advanced head-and-neck cancer patients treated with platinum-based chemotherapy and intensity-modulated radiotherapy and to discuss the findings of their pre-/mid-treatment [(18)F]-misonidazole ((18)F-FMISO) positron emission tomography (PET) scans.
A total of 28 patients agreed to participate in this study. Of these 28 patients, 20 (90% with an oropharyngeal primary cancer) were able to undergo the requirements of the protocol. Each patient underwent four PET scans: one pretreatment fluorodeoxyglucose PET/computed tomography scan, two pretreatment (18)F-FMISO PET/computed tomography scans, and a third (18)F-FMISO PET (mid-treatment) scan performed 4 weeks after the start of chemoradiotherapy. The (18)F-FMISO PET scans were acquired 2-3 h after tracer administration. Patients were treated with 2-3 cycles of platinum-based chemotherapy concurrent with definitive intensity-modulated radiotherapy.
A heterogeneous distribution of (18)F-FMISO was noted in the primary and/or nodal disease in 90% of the patients. Two patients had persistent detectable hypoxia on their third mid-treatment (18)F-FMISO PET scan. One patient experienced regional/distant failure but had no detectable residual hypoxia on the mid-treatment (18)F-FMISO PET scan.
Excellent locoregional control was observed in this series of head-and-neck cancer patients treated with concurrent platinum-based chemotherapy and intensity-modulated radiotherapy despite evidence of detectable hypoxia on the pretreatment (18)F-FMISO PET/computed tomography scans of 18 of 20 patients. In this prospective study, neither the presence nor the absence of hypoxia, as defined by positive (18)F-FMISO findings on the mid-treatment PET scan, correlated with patient outcome. The results of this study have confirmed similar results reported previously.
报告一项对一系列接受铂类化疗和调强放疗的局部区域晚期头颈癌患者进行的前瞻性研究结果,并讨论其治疗前/治疗中期[18F]米索硝唑([18F] - FMISO)正电子发射断层扫描(PET)的结果。
共有28名患者同意参与本研究。在这28名患者中,20名(90%为口咽原发性癌)能够满足方案要求。每位患者接受4次PET扫描:一次治疗前氟脱氧葡萄糖PET/计算机断层扫描,两次治疗前[18F] - FMISO PET/计算机断层扫描,以及第三次[18F] - FMISO PET(治疗中期)扫描,在放化疗开始4周后进行。[18F] - FMISO PET扫描在注射示踪剂后2 - 3小时进行。患者接受2 - 3周期铂类化疗并同时进行根治性调强放疗。
90%的患者在原发灶和/或淋巴结疾病中观察到[18F] - FMISO分布不均。两名患者在第三次治疗中期[18F] - FMISO PET扫描时仍有持续可检测到的缺氧。一名患者出现局部/远处复发,但在治疗中期[18F] - FMISO PET扫描时未检测到残留缺氧。
在这一系列接受铂类化疗和调强放疗的头颈癌患者中,尽管在20名患者中有18名的治疗前[18F] - FMISO PET/计算机断层扫描显示有可检测到的缺氧,但仍观察到了良好的局部区域控制。在这项前瞻性研究中,治疗中期PET扫描上[18F] - FMISO阳性结果所定义的缺氧的存在与否均与患者预后无关。本研究结果证实了先前报道的类似结果。